CD274 and non-small cell lung carcinoma: Subsequently data from the NSCLC cohort [7] led to accelerated approval of pembrolizumab for metastatic PD-L1+ NSCLC with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, in October 2015.